Clinical Trial

Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Study acronym: CaPP3 Israel
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-07-14.
Trial Details
NCT Number NCT02497820
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: Rambam Health Care Campus, Rabin Medical Center, Soroka University Medical Center, Sheba Medical Center
Conditions Lynch Syndrome I (Site-specific Colonic Cancer)
Enrollment 1,800 participants
Start Date 2016-09
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2016-08-25